Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Cyclin-dependent kinases (CDK) 4 and 6 are viable therapeutic target in HER2-positive breast cancer models that functions downstream of HER2.
Tissue based markers are available to direct rational utilisation of selective CDK4/6 inhibitor palbociclib, according to the study performed in a combination of cell culture, mouse models and human primary tumour explants.
The results were presented by Dr Erik Knudsen of the University of Texas Southwestern, Dallas, USA.
Read the article in full here.
Source: ESMO
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.